The Current Ratio as of November 2024 (TTM) for Taysha Gene Therapies, Inc. (TSHA) is 5.51

According to Taysha Gene Therapies, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.51. This represents a change of 21.37% compared to the average of 4.54 of the last 4 quarters.

Taysha Gene Therapies, Inc. (TSHA) Historical Current Ratio (quarterly & annually)

How has TSHA Current Ratio performed in the past?

The mean historical Current Ratio of Taysha Gene Therapies, Inc. over the last ten years is 8.81. The current 5.51 Current Ratio has changed 6.15% with respect to the historical average. Over the past ten years (40 quarters), TSHA's Current Ratio was at its highest in in the December 2020 quarter at 36.17. The Current Ratio was at its lowest in in the December 2019 quarter at 0.

Taysha Gene Therapies, Inc. (TSHA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Taysha Gene Therapies, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Taysha Gene Therapies, Inc. (TSHA) Average Current Ratio

How has TSHA Current Ratio performed in the past?

The current Current Ratio of Taysha Gene Therapies, Inc. (TSHA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Taysha Gene Therapies, Inc. (TSHA) Current Ratio vs. Peers

How is TSHA’s Current Ratio compared to its peers?

Taysha Gene Therapies, Inc.’s Current Ratio is less than Biomea Fusion, Inc. (0), greater than Stoke Therapeutics, Inc. (3.39), greater than Akero Therapeutics, Inc. (5.09), less than Homology Medicines, Inc. (17.25), greater than Gossamer Bio, Inc. (4.19), less than X4 Pharmaceuticals, Inc. (6.74), greater than Inozyme Pharma, Inc. (4.89), less than Terns Pharmaceuticals, Inc. (7.68), less than Day One Biopharmaceuticals, Inc. (32.99), less than HOOKIPA Pharma Inc. (14.62), greater than Monte Rosa Therapeutics, Inc. (3.26), less than Cabaletta Bio, Inc. (6.03), less than Larimar Therapeutics, Inc. (8.11), less than Alector, Inc. (13.10), greater than Shattuck Labs, Inc. (3.29), less than C4 Therapeutics, Inc. (7.96), less than Eliem Therapeutics, Inc. (6.31), less than Prelude Therapeutics Incorporated (60.41), less than null (7.04),

Build a custom stock screener for Taysha Gene Therapies, Inc. (TSHA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Taysha Gene Therapies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Taysha Gene Therapies, Inc. (TSHA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Taysha Gene Therapies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.